What's Happening?
Kernal Biologics, a TechBio company, is set to showcase its mRNA 2.0 platform at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston. The company will present data on its in vivo
CAR T approach, which utilizes targeted lipid nanoparticles (tLNPs) to selectively transduce resting T cells. This method, combined with a machine-learning-based design for mRNA payloads, ensures translation occurs only within target cells. The presentations will demonstrate the platform's ability to achieve rapid B-cell depletion in mouse models, marking a significant step towards making in vivo CAR T therapies safe and scalable.
Why It's Important?
The development of in vivo CAR T therapies represents a potential breakthrough in the treatment of autoimmune diseases and blood cancers. By enabling the programming of T cells directly within the body, Kernal Biologics aims to overcome logistical and toxicological barriers associated with traditional CAR T therapies. This approach could make advanced cell therapies more accessible, allowing them to be administered at any hospital, to any patient, on any day. The success of this platform could significantly impact the biotech industry, offering a new avenue for precision medicine and potentially improving patient outcomes.
What's Next?
Kernal Biologics plans to continue its research and development efforts to further refine its mRNA 2.0 platform. The company is likely to seek regulatory approval for its in vivo CAR T therapies, which could involve additional clinical trials to demonstrate safety and efficacy. The upcoming ASGCT meeting will provide a platform for Kernal Biologics to engage with the scientific community and gather feedback on its approach, potentially influencing future research directions and collaborations.
